A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 206,255 shares of ALNY stock, worth $50.1 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
206,255
Previous 85,990 139.86%
Holding current value
$50.1 Million
Previous $16.5 Million 87.28%
% of portfolio
0.08%
Previous 0.04%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $17.6 Million - $23.8 Million
120,265 Added 139.86%
206,255 $30.8 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $13 Million - $16.9 Million
85,990 New
85,990 $16.5 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $44.1 Million - $73.9 Million
-318,630 Reduced 95.63%
14,570 $2.92 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $40.1 Million - $56.4 Million
333,200 New
333,200 $48.6 Million
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $15.9 Million - $20.8 Million
-99,512 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $3.43 Million - $4.19 Million
-20,177 Reduced 16.86%
99,512 $18.8 Million
Q2 2021

Aug 16, 2021

SELL
$128.63 - $176.89 $41.2 Million - $56.6 Million
-320,248 Reduced 72.79%
119,689 $20.3 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $5.32 Million - $7.37 Million
-41,963 Reduced 8.71%
439,937 $62.1 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $59.3 Million - $70.8 Million
481,900 New
481,900 $62.6 Million
Q3 2019

Nov 15, 2019

SELL
$70.9 - $87.82 $28.3 Million - $35 Million
-398,928 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$65.86 - $92.79 $26.3 Million - $37 Million
398,928 New
398,928 $28.9 Million
Q4 2018

Feb 14, 2019

SELL
$62.67 - $88.33 $55.5 Million - $78.2 Million
-885,312 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$87.52 - $122.67 $41.2 Million - $57.8 Million
-471,096 Reduced 34.73%
885,312 $77.5 Million
Q2 2018

Aug 14, 2018

BUY
$88.31 - $107.8 $39.6 Million - $48.3 Million
448,362 Added 49.38%
1,356,408 $134 Million
Q1 2018

May 15, 2018

BUY
$115.92 - $148.54 $95 Million - $122 Million
819,160 Added 921.58%
908,046 $108 Million
Q4 2017

Feb 14, 2018

BUY
$114.49 - $139.98 $444,908 - $543,962
3,886 Added 4.57%
88,886 $11.3 Million
Q3 2017

Nov 14, 2017

BUY
$72.53 - $118.27 $6.17 Million - $10.1 Million
85,000
85,000 $9.99 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.